Novartis News | finanzen.ch

Kurse + Charts + Realtime		News + Analysen	Fundamental	Unternehmen	zugeh. Wertpapiere	Aktion
Kurs + Chart	Chart (gross)	News + Adhoc	Bilanz/GuV	Termine	Strukturierte Produkte	Portfolio
Times + Sales	Chartvergleich	Analysen	Schätzungen	Profil		Watchlist
Börsenplätze	Realtime Push	Kursziele	Dividende/GV
Historisch			Analysen

Kurse + Charts + Realtime

News + Analysen

Fundamental

Unternehmen

zugeh. Wertpapiere

Strukturierte Produkte

Aktion

Portfolio

Watchlist

21.03.23	Sandoz receives US FDA approval for biosimilar Hyrimoz® (adalimumab-adaz) high-concentration formulation (GlobeNewswire)
20.03.23	Novartis shares Zolgensma long-term data demonstrating sustained durability up to 7.5 years post-dosing; 100% achievement of all assessed milestones in children treated prior to SMA symptom onset (GlobeNewswire)
16.03.23	Novartis Tafinlar + Mekinist approved by FDA for pediatric patients with BRAF V600E low-grade glioma, the most common pediatric brain cancer (GlobeNewswire)
09.03.23	Sandoz signs Memorandum of Understanding to build new biologics production plant in Slovenia, to support increasing global demand for biosimilar medicines (GlobeNewswire)
07.03.23	Aktionärinnen und Aktionäre von Novartis heissen an der ordentlichen Generalversammlung alle Anträge des Verwaltungsrats gut (GlobeNewswire)
07.03.23	Novartis shareholders approve all resolutions proposed by the Board of Directors at the Annual General Meeting (GlobeNewswire)
20.02.23	Novartis announces the appointment of the Chairman-Designate of Sandoz Board of Directors (GlobeNewswire)
22.11.22	Novartis highlights scientific advances with Kisqali, iptacopan, Scemblix and YTB323 data at SABCS and ASH (GlobeNewswire)
07.11.22	New long-term Leqvio® (inclisiran) data from Novartis show sustained efficacy and safety over four years (GlobeNewswire)
07.11.22	Sandoz announces further investment in key manufacturing facility in Austria, to support increased global demand for essential antibiotics (GlobeNewswire)
25.10.22	Novartis maintains growth momentum and confirms FY’22 Group guidance (GlobeNewswire)
25.10.22	Novartis setzt die Wachstumsdynamik fort und bestätigt die Konzernprognose für das Geschäftsjahr 2022 (GlobeNewswire)
24.10.22	Novartis investigational oral monotherapy iptacopan demonstrates clinically meaningful superiority over anti-C5 treatment in Phase III APPLY-PNH study (GlobeNewswire)
14.10.22	Novartis receives positive CHMP opinion for Pluvicto® for patients with progressive, PSMA-positive metastatic castration-resistant prostate cancer (GlobeNewswire)
22.09.22	Novartis unveils new focused strategy, underpinned by eight potential multi-billion dollar peak sales brands & deep pipeline, at Meet the Management event (GlobeNewswire)
21.09.22	Novartis plans to petition the U.S. Supreme Court to uphold validity of the Gilenya® (fingolimod) dosing regimen patent (GlobeNewswire)
19.09.22	Sandoz announces further progress on its biosimilar pipeline, with release of positive results for denosumab integrated Phase I/III clinical trial (GlobeNewswire)
15.09.22	Novartis statement regarding competition authority investigation into assertion of a patent (GlobeNewswire)
10.09.22	Novartis Cosentyx® shows clinically meaningful symptom improvements in patients with hidradenitis suppurativa in pivotal Phase III trials (GlobeNewswire)
09.09.22	Novartis Kisqali® adds one more year of survival benefit for broadest set of patients, including those with aggressive HR+/HER2- advanced breast cancer (GlobeNewswire)
02.09.22	Novartis highlights depth of immunology pipeline with novel data at key upcoming international congresses (GlobeNewswire)
01.09.22	Novartis appoints Fiona Marshall, Ph.D., President of the Novartis Institutes for BioMedical Research as Jay Bradner, M.D., steps down from the Executive Committee of Novartis (GlobeNewswire)
30.08.22	Novartis presents new data in breast and prostate cancer at ESMO (GlobeNewswire)
25.08.22	Novartis will das Sandoz Geschäft durch eine hundertprozentige Ausgliederung als eigenständiges Unternehmen abspalten (GlobeNewswire)
25.08.22	Novartis announces intention to separate Sandoz business to create a standalone company by way of a 100% spin-off (GlobeNewswire)
15.08.22	Novartis provides update on Phase III CANOPY-A study evaluating canakinumab as adjuvant treatment in non-small cell lung cancer (GlobeNewswire)
25.07.22	Applications for proposed first-of-a-kind multiple sclerosis biosimilar natalizumab accepted by US FDA and EMA (GlobeNewswire)
21.07.22	Sandoz Supplemental Biologics License Application accepted by US FDA for biosimilar Hyrimoz® (adalimumab-adaz) high concentration formulation (HCF) (GlobeNewswire)
19.07.22	Novartis erzielt eine anhaltend starke Dynamik der wichtigsten Wachstumsmarken sowie Fortschritte bei strategischen Initiativen und bestätigt die Konzernprognose für das Geschäftsjahr 2022 (GlobeNewswire)
19.07.22	Novartis delivers continued strong momentum of key growth brands, progress on strategic initiatives and confirms FY’22 Group guidance (GlobeNewswire)
30.06.22	New Phase III data show Novartis tislelizumab significantly extended median overall survival by more than 6 months in first-line advanced esophageal cancer in combination with chemotherapy (GlobeNewswire)
24.06.22	Novartis receives positive CHMP opinion for Scemblix®, a novel treatment for adult patients with chronic myeloid leukemia (GlobeNewswire)
23.06.22	Novartis renews commitment to neglected tropical disease and malaria elimination, investing USD 250 million over five years to research and develop new treatments (GlobeNewswire)
23.06.22	Novartis Tafinlar + Mekinist receives FDA approval for first tumor-agnostic indication for BRAF V600E solid tumors (GlobeNewswire)
21.06.22	Novartis plans to petition the U.S. Court of Appeals for the Federal Circuit for further review to uphold validity of the Gilenya® (fingolimod) dosing regimen patent (GlobeNewswire)
17.06.22	Sandoz Application for proposed biosimilar adalimumab’s high concentration formulation accepted by EMA (GlobeNewswire)
16.06.22	New research reveals the critical actions needed to ensure COVID-19-driven surge in virtual health and care drives health access and equity (GlobeNewswire)
12.06.22	Novartis five-year Kymriah® data show durable remission and long-term survival maintained in children and young adults with advanced B-cell ALL (GlobeNewswire)
12.06.22	Novartis five-year Kymriah® data show durable remission and long-term survival maintained in children and young adults with advanced B-cell ALL (GlobeNewswire)
07.06.22	Novartis Scemblix®, with novel mechanism of action, shows superior, long-term efficacy and consistent tolerability in 96-week follow-up of chronic myeloid leukemia trial (GlobeNewswire)
06.06.22	Novartis Tafinlar® (dabrafenib) + Mekinist® (trametinib) demonstrates unprecedented efficacy in pediatric patients with BRAF V600 low-grade gliomas in Phase II/III study (GlobeNewswire)
31.05.22	Sandoz announces new global ‘Act4Biosimilars’ initiative, to improve patient access and increase adoption by at least 30% in 30+ countries by 2030 (GlobeNewswire)
28.05.22	FDA approves Novartis Kymriah® CAR-T cell therapy for adult patients with relapsed or refractory follicular lymphoma (GlobeNewswire)
27.05.22	Sandoz appoints new Board representative to global AMR Industry Alliance (GlobeNewswire)
20.05.22	Novartis Cosentyx® (secukinumab) receives positive CHMP opinion for expanded use in childhood arthritic conditions (GlobeNewswire)
12.05.22	Novartis data at ASCO and EHA showcase latest oncology research and innovation, including in breast and prostate cancer (GlobeNewswire)
04.05.22	New Novartis data demonstrate only Kisqali® offers more life in the first-line setting for postmenopausal HR+/HER2- advanced breast cancer patients (GlobeNewswire)
27.04.22	Novartis tislelizumab plus chemotherapy significantly improved overall survival as first-line treatment for advanced esophageal cancer in Phase III study (GlobeNewswire)
26.04.22	Novartis erzielt ein solides Umsatz- und Gewinnwachstum. Die starke Performance auf dem Markt befindlicher Marken stützt das Vertrauen in die mittelfristigen Wachstumsaussichten (GlobeNewswire)
26.04.22	Novartis delivers solid sales and profit growth. Strong performance of in-market brands supports confidence in mid-term growth outlook (GlobeNewswire)

Newssuche

SMI
SPI
SLI
SMIM
DAX
ESTOXX
Dow Jones
S&P 500
NASDAQ 100
Nikkei 225

Part Grp Hldg	1’263.50	2.89 %	K V
Sonova Hldg	312.10	2.66 %	K V
Novartis	93.68	2.32 %	K V
Geberit	526.80	1.97 %	K V
Roche Hldg G	254.30	1.27 %	K V
Kuehne+Nagel Int	209.50	0.72 %	K V
UBS Group	28.30	0.57 %	K V
Givaudan	3’933.00	0.36 %	K V
Nestle	76.00	0.05 %	K V
Lonza Grp	521.40	-0.04 %	K V

mehr

22.11.24		Dow Jones aktuell: Dow Jones zum Ende des Freitagshandels in der Gewinnzone
22.11.24		Freundlicher Handel in New York: Dow Jones präsentiert sich am Freitagnachmittag fester
22.11.24		Börse New York in Grün: Dow Jones bewegt sich am Mittag im Plus
22.11.24		Zuversicht in London: FTSE 100 beendet die Freitagssitzung in der Gewinnzone
22.11.24		Gute Stimmung in Europa: Anleger lassen STOXX 50 letztendlich steigen
22.11.24		Handel in Frankfurt: TecDAX letztendlich in Grün
22.11.24		Freundlicher Handel: Börsianer lassen SPI schlussendlich steigen